Session » Rheumatoid Arthritis - Clinical Aspects V: Observational Studies in Rheumatoid Arthritis

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 2758

Quantifying The Risk Of Incident Type II Diabetes Following Oral Glucocorticoid Therapy In Patients With Rheumatoid Arthritis: Association With Dose and Duration Of Use

Abstract Number: 2759

Can RA Registries Provide Contextual Safety Data For Modern RCTs?

Abstract Number: 2760

Incidence and Severity Of Myocardial Infarction In Subjects Receiving Anti Tumour Necrosis Factor Drugs For Rheumatoid Arthritis: Results From Linking the British Society For Rheumatology Biologics Register For Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project

Abstract Number: 2761

Comparative Risks Of Herpes Zoster Among RA Patients Switching Biologics In The U.S. Medicare Program

Abstract Number: 2762

Rheumatoid and Psoriatic Arthritis Are Not Associated With Higher Risk Of Incident Diabetes Mellitus

Abstract Number: 2763

Carotid Atherosclerosis As a Predictor Of Mortality In Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.